Real-World study reveals siponimod use in russian MS patients
NCT ID NCT07168694
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked back at medical records of 606 people with secondary progressive multiple sclerosis (SPMS) in Russia who were taking siponimod. Researchers wanted to understand patient characteristics and how the drug was used in everyday practice. The study collected data from 11 MS centers between April and September 2024.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
siponimod
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States